652.91
price down icon0.24%   -1.57
pre-market  Pre-mercato:  655.00   2.09   +0.32%
loading
Precedente Chiudi:
$654.48
Aprire:
$650.41
Volume 24 ore:
1.71M
Relative Volume:
1.62
Capitalizzazione di mercato:
$68.01B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
15.63
EPS:
41.7701
Flusso di cassa netto:
$3.56B
1 W Prestazione:
+11.66%
1M Prestazione:
+16.44%
6M Prestazione:
+14.77%
1 anno Prestazione:
-29.59%
Intervallo 1D:
Value
$637.66
$659.98
Intervallo di 1 settimana:
Value
$572.75
$659.98
Portata 52W:
Value
$476.49
$935.86

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,207
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2025-08-01
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Confronta REGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.25B 4.58B 3.56B 41.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
08:22 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat

08:22 AM
pulisher
08:00 AM

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.

08:00 AM
pulisher
07:45 AM

Regeneron (REGN) Margin Dip Underscores Market Caution Despite Strong Relative Valuation - simplywall.st

07:45 AM
pulisher
06:30 AM

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Evergreen Wealth Management LLC - MarketBeat

06:30 AM
pulisher
04:30 AM

Wealthfront Advisers LLC Sells 1,560 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:30 AM
pulisher
04:13 AM

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlphaQuest LLC - MarketBeat

04:13 AM
pulisher
02:05 AM

Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsMarket Trend Review & High Conviction Buy Zone Picks - newser.com

02:05 AM
pulisher
Oct 29, 2025

Published on: 2025-10-29 21:32:14 - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue $0.88 Quarterly Dividend - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron receives another CRL for its Eylea 8 mg - Ophthalmology Times

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar

Oct 29, 2025
pulisher
Oct 29, 2025

REGN Receives Analyst Rating Boost with New Price Target | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (REGN) Sees Revised Price Target by RB - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? - Barron's

Oct 29, 2025
pulisher
Oct 29, 2025

Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News

Oct 29, 2025
pulisher
Oct 29, 2025

Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues - BioSpace

Oct 29, 2025
pulisher
Oct 29, 2025

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (REGN) Analyst Rating Update: Price Ta - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Opko Health’s ModeX enters license, collab agreement with Regeneron - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

FDA rejects Regeneron’s Eylea HD amid filling facility woes - Pharmaceutical Technology

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript - Insider Monkey

Oct 29, 2025
pulisher
Oct 29, 2025

Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Rallies & Real-Time Volume Analysis - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $767 From $756, Maintains Overweight Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $725 From $640, Maintains Outperform Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Evaluating Regeneron After Recent Pipeline News and Sharp 13% Stock Surge - simplywall.st

Oct 29, 2025
pulisher
Oct 29, 2025

Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $700 From $660, Maintains Buy Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Baird Adjusts Price Target on Regeneron Pharmaceuticals to $630 From $587, Maintains Neutral Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

General American Investors Co. Inc. Sells 5,000 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $780, Maintains Buy Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $788 From $785, Maintains Buy Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Leerink Partners Adjusts Price Target on Regeneron Pharmaceuticals to $710 From $645, Maintains Outperform Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Raymond James Adjusts Price Target on Regeneron Pharmaceuticals to $723 From $673, Maintains Outperform Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $740 From $658, Maintains Overweight Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $800, Maintains Overweight Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More - BioSpace

Oct 29, 2025
pulisher
Oct 29, 2025

Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsBull Run & Stock Timing and Entry Methods - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Teacher Retirement System of Texas Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 29, 2025

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$481.59
price up icon 1.19%
$821.97
price down icon 1.72%
$166.95
price up icon 1.00%
biotechnology ONC
$314.85
price down icon 0.63%
$417.21
price down icon 1.23%
Capitalizzazione:     |  Volume (24 ore):